THERAKOS™ CELLEX™ Photopheresis System Workshop

08 October 2026

Paris, France

Time: 12:00 – 17:50

12:00 – 13:30

Arrival, registration and lunch

13:30 – 13:35

Introduction

Dr Nabih Azar, Hôpital la Pitié Salpêtrière

13:35 – 13:55

Therakos ECP latest updates

Therakos Team

13:55 – 14.15

ECP: Proposed mechanism of action & clinical rationale

Dr Thomas Crépin, CHU de Besançon

14:15 – 14:35

ECP in GvHD: experience of La Pitié Salpêtrière Hospital

Pr Stéphanie Nguyen, Hôpital la Pitié Salpêtrière

14:35 – 14:55

ECP in CTCL: experience of Lille Hospital

Speaker TBC

14:55 – 15:15

ECP in lung transplant: experience of Foch Hospital

Dr François Parquin, Hôpital Foch

15:15 – 15:30

Q&A Session

Dr Thomas Crépin, CHU de Besançon
Pr Stéphanie Nguyen, Hôpital la Pitié Salpêtrière
Speaker TBC
Dr François Parquin, Hôpital Foch

15:30 – 16:00

Break

16:00 – 16:20

Management excellence in apheresis for ECP

Speaker TBC

16:20 – 16:40

TPEP: Therakos process excellence program

Dr Dehbia Menouche, Hôpital Henri Mondor

17:00 – 17:45

Best practices in ECP delivery: Interactive Panel

Moderator: Dr Nabih Azar, Hôpital la Pitié Salpêtrière
Dr Thomas Crépin, CHU de Besançon
Pr Stéphanie Nguyen, Hôpital la Pitié Salpêtrière
Speaker TBC
Dr François Parquin, Hôpital Foch

17:45 – 17:50

Conclusion and key points to remember

Dr Nabih Azar, La Pitié Salpêtrière and Therakos Team

CTCL: Cutaneous T-cell Lymphoma. ECP: Extracorporeal Photopheresis. GvHD: Graft versus Host Disease

All speakers are subject to contract.

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

THERAKOS™ CELLEX™ Photopheresis System Workshop

Time: 12:00 – 17:50

Brought to you by the Therakos Institute

Welcome to the Home of ECP

Thank you for visiting therakos.eu.

You are leaving the therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS